In the past, we’ve covered MagicMed Industries’ psychedelic derivative library, the cleverly titled Psybrary™, quite extensively. It cannot be overstated how instrumental this vast IP-protected drug candidate library will be to moving the psychedelic pharmaceutical industry forward. The Psybrary makes screening for tailored drug candidates easier and allows partners to expedite their products to market. MagicMed initiated the program in July of last year when it filed its first psilocybin derivative patent application and on Tues, Dec. 22nd, announced the completion of the MagicMed psilocybin derivatives intellectual property portfolio and the launch of the Candidate Selection Program.

Readers will recall that within the Psybrary are several portfolios based on the core structures of better-known psychedelics (e.g., psilocybin, DMT, LSD, MDMA, etc.). MagicMed’s initial focus is on psilocybin and dimethyltryptamine (DMT) derivatives, which is a powerful move for several reasons. First, these are one of the compounds that investors and the public is vehemently interested in. Indeed, MagicMed raised $8.1 million before the completion of their psilocybin portfolio was announced, and this will surely spike investor interest further. Second, starting with psilocybin is a great way to capture as much valuable IP as possible because many known psychedelics are based on the same chemical structure

Moreover, the MagicMed psilocybin portfolio announcement is the first time the company is describing these derivatives in detail. They’ve been making countless new molecules and filing numerous patents – and we are finally getting a peak into their innovative and ground-breaking derivatives library.

MagicMed Psilocybin

MagicMed Psilocybin Derivatives Portfolio & Candidate Selection Program

According to MagicMed’s recent press release, the psilocybin derivatives portfolio (which includes DMT derivatives), “includes 12 filed patent applications directed to 9 different chemical compound categories covering over 125 million individual molecules.” This jarring 125 million figure illustrates just how enormous the Psybrary will be when its additional portfolios are completed. This massive grab further solidifies MagicMed’s status as a key player in this emerging industry.

In addition to the psilocybin portfolio, we also learned that MagicMed has launched their Candidate Selection Program. This program is what allows MagicMed’s partners to select drug candidates for screening and development purposes. MagicMed has already synthesized over 100 psilocybin and DMT based derivatives for development by industry partners. 

MagicMed Psilocybin

Understanding Natural Product Patent Challenges

It is paramount to understand why a derivative library is so useful to this industry within our current regulatory framework. The composition of psychedelic compounds in their natural form, such as the psilocybin molecule, are not patentable. In other words, despite the growing licensed research surrounding psilocybin’s therapeutic potential, the drug already exists in nature and thus belongs to the public – one company cannot claim it as intellectual property.

To be sure, a company can attempt to patent a specific use, delivery or manufacturing method for psilocybin, but the letter of the law regarding its patentability is clear. In contrast, the genius of the derivative library is its inherent patentability. The derivatives presented to partners are already IP-protected and ready to capitalize on, further develop, and move forward.

MagicMed Psilocybin

Pharmaceutical Companies Screen Psybrary™ Molecules for Optimal Customization

It is equally paramount to understand how the MagicMed psilocybin derivatives portfolio and candidate selection program makes drug development a faster and smoother process. Especially in psychedelic medicine, there are many different ways a company could utilize a drug candidate. For example, indications such as treating depression and anxiety may speak to a large number of drug companies, but growing research also alludes that psychedelics may treat cluster headaches and even be used as anti-inflammatory agents. This is why MagicMed relentlessly commits to creating numerous molecules: more partners, more diversified revenue, and ultimately more, tailored psychedelic treatment options for patients. Products of all kinds are expedited to the market and are developed for maximum effectiveness with the fewest side effects.

By screening molecules from MagicMed’s Psybrary, pharmaceutical companies are able to select and develop the drug candidates with the greatest potential to complete the regulatory process. Furthermore, partners can be confident that their investment in the development of the drug candidate is protected through MagicMed’s patent portfolio. 

MagicMed Psilocybin

History in the Making

We ought to take a second to consider the gravity of what is taking place here: a company recently announced the completion of an intellectual property portfolio with the potential to cover over 125 million different derivative compounds. Their psilocybin derivative portfolio is just one of many promising portfolios that will be completed (e.g., ibogaine derivatives may be a catalyst to more addiction-focused therapies). The sheer size of patented candidates by MagicMed at this point in time is impressive, and yet, it is only a fraction of the eventual, full-fledged Psybrary they have in the works. This is a great way to enter the space, but more importantly, great news for the psychedelic community and patients with brain and mental health indications that are currently underserved.